ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ELAB
SBFM (27) REVB (36) PPBT (49) PPCB (32) ⌘ Pro Terminal →

PMGC Holdings Inc. (ELAB) — RQD Stock Rating Cockpit

$2.10 -19.23% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.02

PMGC Holdings Inc. (ELAB) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $2.1M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ELAB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ELAB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, PMGC Holdings Inc. (NASDAQ: ELAB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $2.10 (-19.23% 1D, market cap $2.1M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ELAB ranks #898 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ELAB compare to SBFM and REVB in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ELAB carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 31.4%, and ROIC of -35.0%. By comparison, SBFM (Sunshine Biopharma Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -21.4%, cap $2.2M) and REVB (Revelation Biosciences Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $2.3M). Among the 5-stock peer group, ELAB leads on earnings multiple (N/A) while SBFM leads on capital efficiency (-21.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ELAB?
▼

Per ELAB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001840563), PMGC Holdings Inc. generated $590.1K in revenue (-84.4% YoY), -$7.7M in net income, and -$6.4M in free cash flow against $12.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.02 (-3.65%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510027
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (7)Whales (3)SEC (8)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13.8% Base Target
$1566 Bull$2 Base$1 Bear
📬 FREE ELAB RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ELAB)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (27/100 Composite)
🔍 WHY ELAB SCORES 27/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 18.5% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
35
Grade E$2.96-5.1% Next Q
Q2 (-2Q)
32
Grade E$2.81-8.2% Next Q
Q3 (-1Q)
30
Grade E$2.58-18.6% Next Q
Current
27
Grade E$2.10-10.3% Hist 90D α
Trajectory: E (35) → E (27)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ELAB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ELAB currently carries a cautious 27/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.89) and Max Pain ($2.21) forces dealer call-delta covering toward $1,566.43.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ELAB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ELAB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 27%NO 73%Trade / Inspect Odds →
RSI-14 MOMENTUMOVERSOLD (<32)
27.230 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
3 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $3$2.10H: $1,492
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 6 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 14 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on ELAB

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (35)

-35.0% ROIC with 31.4% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (40)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (20)

6/40 institutional & smart-money positioning score with 6/20 macro alignment.

Bull Case: Why Buyers Like ELAB
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ELAB)

  • ✓Walkthrough of ELAB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ELAB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -90.99%⚡ TESTING RESISTANCE
2026-11-03O $2.64H $2.64L $2.10C $2.10VOL 7.5K
RES: $3.30SUP: $-2.89SMA50: $3.89SMA200: $33.50
$878.3$640.9$403.4$165.9$-71.60RES $3.30SUP $-2.89$2.102026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ELAB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ELAB Butterfly Map → + Track ELAB →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ELAB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ELAB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ELAB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ELAB)

Health Care Rank #898 of 1016 ⚔️ SBFM vs ELAB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ELAB vs. SBFM, REVB, PPBT, PPCB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, PMGC Holdings Inc. (ELAB) ranks #898 by composite RQD confidence (27/100, grade E) and #994 by equity capitalization ($2.1M). Within this direct 5-issuer industry benchmark cohort, ELAB leads on earnings valuation at N/A trailing P/E, while SBFM leads on capital efficiency and profitability with -21.4% ROIC and 33.8% gross margin. PPBT currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with ELAB at 27/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ELAB ACTIVE
PMGC Holdings Inc.
E 27/100 — 31.4% -35.0% -19.23% $2.1M Benchmark Subject
SBFM
Sunshine Biopharma Inc.
E 27/100 — 33.8% -21.4% -6.14% $2.2M /sbfm-vs-elab →
REVB
Revelation Biosciences Inc.
D- 36/100 — — -35.0% +0.50% $2.3M /revb-vs-elab →
PPBT
Purple Biotech Ltd.
D 49/100 — — — +5.13% $1.9M /ppbt-vs-elab →
PPCB
Propanc Biopharma Inc.
E 32/100 — — -35.0% -6.52% $1.9M /ppcb-vs-elab →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001840563

In its most recent audited fiscal period (FY2025, filed 2025-12-31), PMGC Holdings Inc. (ELAB) reported GAAP revenue of $590.1K (-84.4% vs. FY2024 revenue of $3.8M , and -65.5% cumulative change since FY2023) , GAAP net income of -$7.7M, operating cash flow of -$5.9M, and free cash flow of -$6.4M (-16.0% YoY). On the balance sheet, ELAB closed FY2025 with $12.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $590.1K -$7.7M -$5.9M -$6.4M $12.9M —
FY2024 (FY) 2024-12-31 $3.8M -$6.2M -$5.5M -$5.5M $9.0M —
FY2023 (FY) 2023-12-31 $1.7M -$4.3M -$4.6M -$4.6M — —

3. ELAB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ELAB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, PMGC Holdings Inc. (NASDAQ: ELAB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $2.10 (-19.23% 1D, market cap $2.1M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ELAB ranks #898 in composite RQD confidence.

How does ELAB compare to SBFM and REVB in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ELAB carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 31.4%, and ROIC of -35.0%. By comparison, SBFM (Sunshine Biopharma Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -21.4%, cap $2.2M) and REVB (Revelation Biosciences Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $2.3M). Among the 5-stock peer group, ELAB leads on earnings multiple (N/A) while SBFM leads on capital efficiency (-21.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ELAB?

Per ELAB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001840563), PMGC Holdings Inc. generated $590.1K in revenue (-84.4% YoY), -$7.7M in net income, and -$6.4M in free cash flow against $12.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ELAB trading relative to its 50-day, 200-day, and 52-week technical levels?

ELAB last traded at $2.10 (-19.23% on volume of 12,757,896 shares), positioning the stock -46.02% below its 50-day simple moving average ($3.89) and -93.73% below its 200-day simple moving average ($33.50). Across its 52-week range of $2.51 to $1,491.84, ELAB sits at the 0.0% percentile with a 14-day RSI of 27.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.84 to $2.36).

Direct Sub-Reports: ELAB RQD Cockpit ELAB 12M Forecast ELAB Earnings & Move ELAB Dividends & DRIP ELAB Insiders & 13F ELAB Whale Options ELAB Profit Sankey ELAB News & Why
ROARABLE RATING BRIEF • RQD 27/100 (E) ✓ SEC XBRL & RQD VERIFIED

ELAB — PMGC Holdings Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

PMGC Holdings Inc. (ELAB) earns a live Roarable RQD composite score of 27/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.10 (-19.23% 1D, market capitalization $2.1M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 31.4%, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (8/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (3/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

PMGC Holdings Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the financials section, the company reported revenue of $0.6M in FY 2025 and $1.7M in FY 2023, with — reported for FY 2024.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), PMGC Holdings Inc. (ELAB) reported $590.1K in annual revenue (up from $3.8M in FY2024, -84.4% YoY) and -$7.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.7M revenue, -$4.3M net income) through FY2025, ELAB scaled operating cash flow to -$5.9M and free cash flow to -$6.4M, backed by $12.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 27/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.51 – $1,491.84 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— the supply_chain field is NONE and the butterfly_links and proprietary_signals arrays are empty, so the source data identifies no upstream or downstream dependencies, sector correlation links, or second-order bottlenecks.

  • Key Question #1: Can ELAB sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $590.1K and free cash flow of -$6.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ELAB's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ELAB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for PMGC Holdings Inc. (ELAB) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ELAB Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ELAB Bull vs. Bear Conversation Board — What's Your Call at $2.10?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ELAB 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ELAB:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $3.38 (+30.0%)
📌 Pinned Debate

The balance-sheet pillar is the strongest component at 8/20 with an Altman Z-Score of 2.5 and Debt/Equity of 0.5, and the stock traded

Here is why I am bullish on ELAB here at $2.60: The balance-sheet pillar is the strongest component at 8/20 with an Altman Z-Score of 2.5 and Debt/Equity of 0.5, and the stock traded up 2.72% in the latest session.. Compare ELAB's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $2.47 are getting bought.

EarningsSniper 🐂 BULL

@SkepticalCFA Shorting a 3/20 institutional whale-flow stock at $2.60 is dangerous when funds are rotating into Health Care.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $1.95 (-25.0%)
Spot @ $2.60

Negative ROIC of -35%, zero FCF yield, and a Piotroski F-Score of 3/9 combine with a Roarable Strong Sell verdict and net losses in eve

I respect the product at PMGC Holdings Inc., but the stock at $2.60 is a different story. Negative ROIC of -35%, zero FCF yield, and a Piotroski F-Score of 3/9 combine with a Roarable Strong Sell verdict and net losses in every reported period.. FCF yield is 0.0% and RQD sits at 27/100 (E) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%